ALEXANDRA REBMAN: Open Payments
NPI 1568246544 · DOUGLASVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$876 in 36 payments from 19 companies in 2025. Trend: 2023 $23 · 2024 $1,132 · 2025 $876
Food & beverage: $876
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $160 |
| PFIZER INC. | 6 | $136 |
| AstraZeneca Pharmaceuticals LP | 3 | $80 |
| Janssen Biotech, Inc. | 3 | $73 |
| Merck Sharp & Dohme LLC | 2 | $53 |
| Genentech USA, Inc. | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $45 |
| TAIHO ONCOLOGY, INC. | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $28 |
| PharmaEssentia USA Corporation | 1 | $28 |
Products named: KISQALI, IBRANCE, KEYTRUDA, DARZALEX, Enhertu, VENCLEXTA, Polivy, LONSURF.
Industry payments across GA — which companies pay providers there.
